Grant of Options

RNS Number : 9328P

ReNeuron Group plc

15 February 2023

 

ReNeuron Group plc

("ReNeuron" or "the Company" or "the Group")

Grant of Options

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies , announces that grants were made on 14 February 2023 for options over 4,030,000 Ordinary Shares of 1p each ("Options") under the terms of the Company's Long Term Incentive Plan ("The Plan") and its Non-Executive Share Option Scheme.  The grants of 3,000,000 Options made to Directors and Persons Discharging Managerial Responsibilities (PDMRs) are set out further in the table below.

1,615,000 of the Options granted under The Plan have an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days.

The remaining 1,415,000 of the Options granted under The Plan have an exercise price of 31.5 pence per share. The Options vest in equal proportions at 12, 24 and 36 months from the date of grant. None of these Options are subject to any further performance conditions.

The 1,000,000 Options granted to Iain Ross are granted under the Non-Executive Share Option Scheme. 750,000 of the Options are granted with an exercise price of 10.25 pence per share, this being the closing mid-market price of the Company's shares on 14 February 2023. These Options will be exercisable if the share price of the Company's shares exceeds 31.5p for any single period of at least 30 consecutive days. 250,000 of the Options are granted with an exercise price of 50.0 pence per share without any further performance conditions. All of Mr Ross's options vest monthly over three years on a straight-line basis.

Name	Title	Date of grant of Options	Number of Options granted	Total shares over which options are held (post award)	Percentage of issued shares under option
Iain Ross	Executive Chairman	14 February 2023	1,000,000	1,500,000	2.62%
John Hawkins	Chief Financial Officer	14 February 2023	500,000	840,000	1.47%
Randolph Corteling	Chief Scientific Officer	14 February 2023	500,000	1,000,000	1.75%
Simon Dew	Chief Business Officer	14 February 2023	600,000	600,000	1.05%
Suzanne Hancock	Chief Operations Officer	14 February 2023	400,000	749,326	1.31%

  ENDS

Enquiries:

ReNeuron		www.reneuron.com/investors
Iain Ross, Chairman		Via Walbrook PR
John Hawkins, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking)		[phone]
Allenby Capital Limited (Joint Broker)		[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.  ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to grant of share options to Directors and PDMRs)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Iain Ross
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 0.00 1,000,000
d)	Aggregated information	N/A
e)	Date of the transaction	14 F e bruary 2023
f)	Place of the transaction	Outside of a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	John Hawkins
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 0.00 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	14 February 2023
f)	Place of the transaction	Outside of a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Randolph Corteling
2	Reason for the notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 0.00 500,000
d)	Aggregated information	N/A
e)	Date of the transaction	14 February 2023
f)	Place of the transaction	Outside of a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Simon Dew
2	Reason for the notification
a)	Position/status	Chief Business Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 0.00 600,000
d)	Aggregated information	N/A
e)	Date of the transaction	14 F ebruary 2023
f)	Place of the transaction	Outside of a trading venue

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Suzanne Hancock
2	Reason for the notification
a)	Position/status	Head of Operations
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)	Price(s)  Volume(s) 0.00 400,000
d)	Aggregated information	N/A
e)	Date of the transaction	14 February 2023
f)	Place of the transaction	Outside of a trading venue

 

END

 

 

DSHKZLFFXLLZBBD